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Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is a cerebral
small vascular disease caused by NOTCH3 mutation-induced vascular smooth muscle cell (VSMC) degeneration,
leading to ischemic stroke and vascular dementia. Our previous study has demonstrated that repeated treatment with
a combination of stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) reduces VSMC degeneration and cerebral endothelial cell (EC) damage and improves cognitive function in a mouse model of CADASIL
(TgNotch3R90C). This study aimed to determine whether cerebral thrombosis occurs in TgNotch3R90C mice and
whether repeated SCFþG-CSF treatment reduces cerebral thrombosis in TgNotch3R90C mice. Using the approaches
of bone marrow transplantation to track bone marrow-derived cells and confocal imaging, we observed bone
marrow-derived blood cell occlusion in cerebral small vessels and capillaries (thrombosis). Most thrombosis occurred
in the cerebral capillaries (93% of total occluded vessels), and the thrombosis showed an increased frequency in the
regions of capillary bifurcation. Degenerated capillary ECs were seen inside and surrounding the thrombosis, and
the bone marrow-derived ECs were also found next to the thrombosis. IgG extravasation was seen in and next to the
areas of thrombosis. SCFþG-CSF treatment significantly reduced cerebral capillary thrombosis and IgG extravasation.
These data suggest that the EC damage is associated with thrombosis and blood–brain barrier leakage in the cerebral
capillaries under the CADASIL-like condition, whereas SCFþG-CSF treatment diminishes these pathological alterations. This study provides new insight into the involvement of cerebral capillary thrombosis in the development of
CADASIL and potential approaches to reduce the thrombosis, which may restrict the pathological progression of
CADASIL.
Keywords
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Introduction
Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leucoencephalopathy (CADASIL) is the most
common form of hereditary disease leading to recurrent
ischemic stroke and vascular dementia1. The disease is
caused by a dominant mutation in the NOTCH3 gene encoding Notch3 receptor2, resulting in the degeneration of vascular smooth muscle cells (VSMCs) in small arteries and
cerebral capillary pericytes3. The affected vessels are generally the pial arteries, small penetrating arteries, and arterioles
in the cerebrovasculature4. Although VSMCs are mainly
affected in the CADASIL disease5,6, accumulating evidence
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has shown that endothelial cell (EC) damage/dysfunction is
also seen in CADASIL7–9.
ECs are located on the interior surface of blood vessels
and form a barrier that separates the blood from the surrounding tissue10. In addition to regulating vascular tone
and cell adhesion, ECs also serve as a hemocompatible
barrier that helps to maintain blood flow or promote blood
coagulation11. Once ECs are injured, cellular and protein
materials aggregate at the site of injury and form a blood
clot (thrombosis). During the development of thrombosis,
the vessels are occluded, resulting in blocked blood flow and
EC degeneration in the occluded area of the vessels12.
Together with the hemodynamic alterations, impairments
of cerebrovascular ECs lead to increased permeability of the
blood–brain barrier (BBB) and dysregulated entrance of
nutrients from the blood into the brain and clearance of waste
products from the brain to the blood13, ultimately resulting in
brain damage. The common causes of EC damage include
inflammation, oxidative stress, and mechanical stress
induced by disturbed blood flow14. How the CADASILassociated NOTCH3 mutation causes injuries of the cerebrovascular system, however, still remains unclear.
Stem cell factor (SCF) and granulocyte colonystimulating factor (G-CSF) are the essential hematopoietic
growth factors that regulate blood cell production and bone
marrow cell survival, proliferation, and mobilization15. In
addition to the important function in the hematopoietic system, SCF and G-CSF also play roles in the nervous system.
SCF and G-CSF reduce brain damage and improve motor
function in the acute and subacute phases of stroke16,17.
SCF and G-CSF can pass the BBB18,19 and show direct
effects in promoting neurite outgrowth 20 . Systematic
administration of SCF and G-CSF (SCFþG-CSF) also promotes brain repair in the chronic phase of stroke21–25. Our
earlier study has demonstrated that repeated SCFþG-CSF
treatment prevents VSMC degeneration, reduces cerebrovascular EC damage, and improves cognitive function in a
mouse model of CADASIL carrying the human mutant
NOTCH3 gene in the VSMCs (TgNotch3R90C)9. The aim
of the present study was to examine whether cerebral
thrombosis occurs in TgNotch3R90C mice and whether
repeated SCFþG-CSF treatment reduces cerebral thrombosis in TgNotch3R90C mice.

Materials and Methods
Animals and Treatment
All experiments were approved by the Institutional Animal
Care and Use Committee and conducted according to
National Institutes of Health guidelines. The inclusion and
exclusion criteria were defined before starting the experiment, which was in line with the standard animal care guideline. If mice showed severe health problems, these mice
were euthanized before the end of the study. These mice
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would not be included in the study. The experiment was
performed in a randomized and a blind manner.
Transgenic mice carrying a full-length human NOTCH3
gene with the Arg90Cys mutation driven by the SM22a promoter in VSMCs were used as the mouse model of CADASIL26. At 8 months of age, male TgNotch3R90C mice
received a lethal dose of radiation (900 rad) to destroy their
own bone marrow. Within 24 h, bone marrow from mice
ubiquitously expressing green fluorescent protein (GFP) was
transplanted to the irradiated TgNotch3R90C mice. After 1
month of recovery, TgNotch3R90C mice were randomly
divided into two groups: a control group (n¼5) and an
SCFþG-CSF- treated group (n¼5). The first treatment was
initiated at 9 months of age, which is 1 month before
cerebrovascular dysfunction is shown in the TgNotch3R90C
mice26,27. Recombinant mouse SCF (100 mg/kg) (PeproTech,
Rocky Hill, NJ, USA) and recombinant human G-CSF (50 mg/
kg) (Amgen, Thousand Oaks, CA, USA) were subcutaneously
administrated for 5 consecutive days. An equal volume of
saline was injected into control mice. The same treatment was
then repeated on an additional four occasions at ages of 10, 12,
15, and 20 months. The final treatment was given at 200 mg/kg
of SCF and 50 mg/kg of G-CSF. The rationale for the increase
of the SCF dosage at the final treatment was that (1) it has
been shown that pathological changes in the brain become
much more severe after 18 months of age in TgNotch3R90C
mice26,27, and (2) our previous studies have revealed that 200
mg/kg of SCF and 50 mg/kg of G-CSF were more therapeutically effective than 100 mg/kg of SCF and 50 mg/kg of G-CSF
in animal models of ischemic stroke28. Mice were sacrificed
at the age of 22 months. Age-matched wild-type mice were
used as normal controls (n¼5).

Bone Marrow Transplantation
To visualize blood clots (thrombosis) and bone marrowderived ECs in the cerebral vessels of TgNotch3R90C mice,
the bone marrow of the transgenic mice ubiquitously expressing enhanced GFP under the control of the human ubiquitin
C promoter (UBC-GFP) was transplanted into the
TgNotch3R90C mice (C57BL/6 background, a gift from Dr
Anne Joutel’s lab). UBC-GFP mice (male, 6–8 weeks old;
C57BL/6 background, Jackson Laboratory) were anesthetized
with Avertin (0.4g/kg body weight, intraperitoneally (i.p.);
Sigma-Aldrich, St. Louis, MO, USA). The femur bones were
dissected and placed into a dish with ice-cold sterile Hanks
Balanced Salt Solution (HBSS; ThermoFisher Scientific,
Pittsburgh, PA, USA). Bone marrow cells were flushed out
with a 25G needle. Cells were gently triturated with a 10 ml
pipette, filtered through a 70 mm nylon mesh (Corning, Fisher
Scientific, Pittsburgh, PA, USA) and collected in a 50 ml tube
(Corning, Fisher Scientific, Pittsburgh, PA, USA). Harvested
cells were centrifuged and re-suspended with HBSS into single cell suspension. Cells were transplanted to irradiated
TgNotch3R90C mice by tail vein injection (1107 bone marrow cells in 0.6 ml HBSS per mouse).
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Brain Tissue Preparation
At the age of 22 months, mice were anesthetized with Avertin
and sacrificed by transcardial perfusion of phosphate-buffered
saline (PBS; ThermoFisher Scientific, Pittsburgh, PA, USA)
followed by 10% formalin (Sigma-Aldrich, St. Louis, MO,
USA). Brains were collected and post-fixed in the same fixative solution overnight at 4 C. Brains were dehydrated with
30% sucrose (Sigma-Aldrich, St. Louis, MO, USA) in 0.1 M
PBS for 2 days at 4 C. Brain sections (30 mm) were cut by
cryostat (Leica Biosystems, Wetzlar, Germany).

Immunohistochemistry
Four adjacent brain sections per mouse (bregma –0.34 mm)
were used for immunohistochemistry, two sections for
CD31/GFP double labeling, and two for IgG immunostaining. Brain sections were rinsed with PBS three times for 5
min each. Sections were incubated with 10% normal donkey
serum (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA) in PBS containing 1% bovine serum albumin
(BSA; Sigma-Aldrich, St. Louis, MO, USA) and 0.3%
TritonX-100 (Sigma-Aldrich, St. Louis, MO, USA) for 1 h
at room temperature to block nonspecific staining. After
blocking, brain sections were incubated with purified rat
anti-mouse CD31 (1:50; BD biosciences, San Jose, CA,
USA) and goat anti-mouse GFP (1:600; Novus Biologicals,
Littleton, CO, USA) primary antibodies at 4 C overnight.
The next day, sections were washed with PBS three times
and incubated with TRITC-conjugated donkey anti-rat
(1:200; ThermoFisher Scientific, Pittsburgh, PA, USA) and
Alexa-Fluor 488-conjugated donkey anti-goat (1:200; Life
technology, Carlsbad, CA, USA) in the dark at room temperature for 2 h. To determine IgG deposition, brain sections
were blocked with mouse on mouse blocking reagent
(M.O.M.TM; Vector Laboratories, Burlingame, CA, USA)
for 1 h at room temperature. The brain sections were then
incubated with biotin conjugated goat anti-mouse IgG
(whole molecule) antibody (1:200) at 4 C overnight. The
next day, brain sections were incubated with CY3 conjugated
streptavidin (Thermo Fisher Scientific, Pittsburgh, PA, USA)
in the dark for 2 h at room temperature. The antibodies were
all diluted in PBS containing 1% BSA and 0.3% TritonX-100.
Nuclei were stained with mounting medium (VECTASHIELD; Vector Laboratories, Burlingame, CA, USA).
Images of the affected cerebral vessels in the brain (including
the cortex and striatum) were taken with a Zeiss 780 confocal
microscope (Carl Zeiss, Jena, Germany).

Statistical Analysis
Data analysis was performed in a blind manner. Two-group
comparisons were analyzed using a Student’s t-test or
Mann–Whitney test depending on the distribution of the
data. One-way analysis of variance (ANOVA) was used to
analyze differences in three experimental groups followed
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by Tukey’s post-hoc multiple comparison tests. Results were
considered significant when a p value is less than 0.05. Normal distribution data are presented as mean + S.D, and
nonparametric data are presented by box-and-whisker plots.
Analyses were performed, and data were displayed using
Prism software (GraphPad Software, Inc., La Jolla, CA,
USA).

Results
Thrombosis Occurs in the Cerebral Capillary and Small
Vessels of TgNotch3R90C Mice
To determine the involvement of thrombosis in CADASIL
pathogenesis, we first examined thrombotic formation in
cerebral blood vessels by immunofluorescence double labeling of CD31 (the ECs marker) and GFP (bone marrowderived cells) (Fig. 1). We used CD31 antibody to show the
wall of all blood vessels and GFP to visualize blood clots
occluded in the blood vessels. Cells that co-express CD31
and GFP were considered bone marrow-derived ECs.
We observed that some capillaries (<10 mm in diameter)
and small vessels (>10 mm in diameter) in the cortex and
striatum were filled with bone marrow-derived GFP positive
blood cells (Fig. 1A, C–E), suggesting that blood clots
(thrombosis) occlude the capillaries and small vessels. In
addition, bone marrow-derived GFP positive cells coexpressed the EC marker CD31 were also seen in the brain
capillaries (Fig. 1B’ and B’’), suggesting that they are bone
marrow-derived ECs. The bone marrow-derived ECs
appeared next to the location of thrombosis (Fig. 1A–E,
B’, B’’, and E’). Moreover, degenerated ECs with scattered
CD31 positive debris in the lumen of capillaries were found
within and surrounding the thrombosis (Fig. 1E’ and E”).
We also observed that the ECs within the thrombosis and on
the wall of the cerebral capillary with thrombosis were
caspase-3 positive, indicating these ECs undergo apoptosis
(Fig. 2A–C). Taken together, these findings suggest that
EC damage/degeneration may lead to bone marrowderived EC replacement, and that damaged/degenerated
ECs may trigger blood clot formation (thrombosis) under
a CADASIL-like condition.
Platelets play a key role in vascular thrombotic formation29. Using immunofluorescence double staining and
confocal imaging, we observed that CD41 positive platelets were co-localized with GFP positive blood cells in
the thrombosis (Fig. 2D). This finding confirms that
platelet-involved thrombosis occurs in the brains of
TgNotch3R90C mice.
The vast majority of thrombosis in TgNotch3R90C
mouse brain appeared in the cerebral capillaries (93%),
while only 7% of total occluded vessels were small vessels
(Fig. 3A). By analyzing the localization of the thrombosis,
we found that the thrombosis formation showed a significantly high rate in the bifurcation of the blood vessel in the
brains of TgNotch3R90C mice (p<0.05) (Fig.3B-E). These
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Fig. 1. Confocal images show that bone marrow-derived GFP-positive cells occlude the cerebral blood vessels and replace the endothelial
cells of cerebral capillaries and small vessels in 22-month-old TgNotch3R90C mice. (A) Three-dimensional image shows that bone
marrow-derived GFP positive cells (green) either occlude the capillaries (<10 mm in diameter) and small blood vessels (>10 mm in diameter)
or co-express the endothelial cell marker CD31 (red) in the brain of a 22-month-old TgNotch3R90C mouse. White arrows indicate GFP
positive cells co-expressing CD31 in the capillaries. (B) Two selected areas (see the white arrows labeled with B in panel A), B’ and B’’.
Detailed images of every channel (red: CD31-positive endothelial cells; green: bone marrow-derived cells; blue: DAPI, nuclear staining) are
displayed in B’1–B’3 and B’’1–B’’3. B’4 and B’’4: merged images of B’1–B’3 and B’’1–B’’3, respectively. (C and D) Three-dimensional images
illustrate that GFP positive cells occlude in a cerebral small vessel and two capillaries at two different cross-sectional layers, where are
intermediate to the sections B and E (see the labeled area with C, D in panel A). (E) Two selected areas (see the arrowheads labeled with E in
panel A), E’ and E’’. Each of the three channels (red: CD31 positive endothelial cells; green: bone marrow-derived cells; blue: DAPI, nuclear
staining) in the capillaries selected in E’ and E’’ are displayed in E’1–E’3 and E’’1–E’’3. E’4 and E’’4: merged images of E’1–E’3 and E’’1–E’’3,
respectively. These cross-sections (B–E) display the endothelial cell damage/degeneration, endothelial cell replacement by bone marrowderived endothelial cells (CD31þ/GFPþ), and blood clots (thrombosis) that occlude cerebral capillaries and small vessels. Note that images
from B, C, D, and E are the cross-sections showing from up to down layers of image A. Scale bars, 20 mm.

data indicate that cerebral capillary thrombosis is a key
pathological feature of CADASIL.

SCFþG-CSF Treatment Reduces Capillary Thrombosis
Formation in TgNotch3R90C Mice
Next, we sought to determine whether SCFþG-CSF treatment
could reduce thrombosis formation in the brains of mice carrying Notch3R90C mutations. Since the occluded small vessels occupied only 7% of the total occluded blood vessels,
whereas the occluded capillaries held 93%, we selected the
occluded capillaries to examine the inhibitive efficacy of
SCFþG-CSF treatment on capillary thrombosis formation.
We observed that the capillary thrombosis formation at
the vascular branching areas was significantly reduced by
SCFþG-CSF treatment (p<0.05) (Fig. 3F). In control

TgNotch3R90C mice, 80% of capillary thrombosis occurred
in vascular bifurcation areas, whereas only 25% of capillary
thrombosis happened in the bifurcation regions in SCFþGCSF-treated TgNotch3R90C mice (Fig. 3G). This observation suggests that SCFþG-CSF treatment may attenuate the
CADASIL-associated pathological changes in cerebral
capillary hemodynamics.
In addition, the total areas of GFP positive blood cell
occlusions in the capillaries showed a trend (0.05<p<0.1)
towards decreasing in the SCFþG-CSF-treated
TgNotch3R90C mice (p¼0.06) (Fig. 4C). The total length
of the blood-occluded capillaries was reduced significantly
after SCFþG-CSF treatment (p<0.05) (Fig. 4D). These findings indicate that the SCFþG-CSF treatment can diminish
the occurrence of thrombosis in the cerebral capillaries of
TgNotch3R90C mice.

Ping et al
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Fig. 2. Confocal images illustrate apoptotic endothelial cells and bone marrow-derived GFP-positive platelets at the location of capillary
thrombosis in the brains of 22-month-old TgNotch3R90C mice. (A–C) Three-dimensional (3D) image shows caspase-3 (white) and CD31
(red) double-positive cells within the thrombosis (A) and on the wall of the cerebral capillary with thrombosis (B). Merged 3D image of
panels A and B with added GFP-expressing cells shows the location of apoptotic endothelial cells (caspase-3þ/ CD31þ) in the thrombosis of
cerebral capillary (C). Note that bone marrow-derived endothelial cells undergo apoptosis (GFPþ/caspase-3þ/ CD31þ) within the thrombosis (C). Scale bars, 20 mm. (D) Three-dimensional image shows that bone marrow-derived GFP-positive cells (green) co-express platelet
marker CD41 (red) in the thrombosis of cerebral capillary. Scale bar, 10 mm.

SCFþG-CSF Inhibits Capillary Leakage in the Brains
of TgNotch3R90C Mice
Immunoglobulin G (IgG) extravasation has been used as an
indicator of a leakage in the BBB30. In this study, we used
IgG immunostaining to detect capillary leakage in cerebral
cortex and striatum (Fig. 5).
ECs are the major components of the BBB in the brain.
The dysfunction or injury of ECs impairs the integrity of the
BBB, resulting in BBB leakage in the brain. In addition to
the thrombotic formation, we also found that the IgG deposition area in the capillaries was increased significantly in the
brains of TgNotch3R90C mice as compared with the agematched WT controls (p<0.001) (Fig. 5A, B, and D), suggesting that the BBB leakage and dysfunction/degeneration
of ECs occur in the brains of TgNotch3R90C mice.

However, after SCFþG-CSF treatment, the positive area of
IgG staining in the capillaries was reduced significantly
(p<0.05) (Fig. 5B, C, and D). By 3D imaging, we noted that
the IgG-positive staining was localized within and around
the occluded material (thrombosis) that was composed of the
bone marrow-derived GFP positive blood cells (Fig. 5E, E,
and E’’). These data further confirm that the damage in the
ECs of cerebral capillaries happens in TgNotch3R90C mice,
and that SCFþG-CSF treatment reduces the cerebral capillary EC damage and diminishes BBB leakage in mice with
CADASIL-associated gene mutations.

Discussion
Using the mice carrying human CADASIL-related
NOTCH3 mutation in the VSMCs (TgNotch3R90C mice),
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Fig. 3. Bone marrow-derived GFP-positive cells occlude in small vessels and at the bifurcation and non-bifurcation regions of cerebral
capillaries in 22-month-old TgNotch3R90C mice. SCFþG-CSF treatment significantly reduces the occurrence of blood occlusion (thrombosis) at the bifurcation regions of the cerebral capillaries in the TgNotch3R90C mice. (A) A pie chart shows the percentage of bone
marrow-derived GFP-positive blood cell-occluded (green) cerebral small vessels (>10 mm in diameter) and capillary (<10 mm in diameter).
(B) A pie chart displays the percentage of the blood occlusion (thrombosis) that occurs at the non-branching area or branching area of
cerebral capillaries, which is calculated from all the mice including both SCFþG-CSF-treated and non-treated TgNotch3R90C mice. (C) A
representative confocal image shows that bone marrow-derived GFP positive blood cells occlude in the non-branching area of a cerebral
capillary. (D) A representative confocal image illustrates the cerebral capillary occlusion by bone marrow-derived GFP positive blood cells in
the branching area of capillaries. (E) Statistical analysis data show that the number of blood clot-occluded capillaries in the branching area is
significantly increased in the brains of TgNotch3R90C mice. (F) Statistical analysis data display that the number of blood clot-occluded
capillaries at capillary bifurcation areas in the brains of TgNotch3R90C mice is reduced significantly by SCFþG-CSF treatment. (G) Pie
graphs illustrate the percentage of capillary thrombosis at the bifurcation or non-bifurcation regions, which is calculated from the brains of
SCFþG-CSF-treated or non-treated TgNotch3R90C mice, respectively. Data are presented by box-and-whisker plots in E and F. Here
N¼5. * p<0.05. Scale bars, 20 mm.

Fig. 4. SCFþG-CSF treatment reduces the capillary thrombosis in the brains of 22-month-old TgNotch3R90C mice. (A and B) Representative confocal images show blood occlusion (thrombosis) (GFP positive green vessels) in the cerebral capillaries of a control
TgNotch3R90C mouse (A) and an SCFþG-CSF-treated TgNotch3R90C mouse (B). (C) Statistical analysis data. Noting that SCFþGCSF-treated TgNotch3R90C mice show a trend toward decreased percentage of thrombotic area. (D) Statistical analysis data show that
the length of blood-occluded capillaries (GFP positive) is decreased significantly in the SCFþG-CSF-treated TgNotch3R90C mice. Here
N¼5. * p<0.05. Scale bar, 20 mm.

this study has, for the first time, revealed that (1) thrombosis formation occurs in both the cerebral capillary and
small vessels, whereas the vast majority of thrombosis

happens in the cerebral capillary, (2) the cerebral capillary thrombosis has a significantly high frequency in the
branching region of capillaries, and (3) SCFþG-CSF

Ping et al
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Fig. 5. SCFþG-CSF treatment reduces IgG deposition in the cerebral cortex of 22-month-old TgNotch3R90C mice. (A–C) Representative
images show IgG-positive immunofluorescent staining in the cerebral cortex of an age-matched wild-type (WT) mouse (A), a control
TgNotch3R90C mouse (B) and an SCFþG-CSF-treated TgNotch3R90C mouse (C). (D) Statistical analysis data. Noting that the percentage
of IgG-positive areas in the brains of control TgNotch3R90C mice is increased significantly as compared with the WT mice, whereas
SCFþG-CSF treatment leads to significant reductions of IgG deposition. (E, E’, and E’’) Three-dimensional confocal images show that the IgG
positive staining is localized within and around the occluded material that is composed of the bone marrow-derived GFP positive blood cells.
Here N¼5. * p<0.05, **p<0.01. Scale bar in C, 20 mm, the indicator for panels A–C.

repeated treatment inhibits cerebral capillary thrombosis
and capillary leakage.

Cerebral EC Damage is Involved in the Pathogenesis
of CADASIL Disease
It has long been known that CADASIL is a VSMC degenerative disease. ECs would not be affected in this disease.
However, a growing body of evidence has revealed that
impaired ECs exist in both CADASIL patients and transgenic mouse models of CADASIL. Using electron microscopy, Ruchoux and Maurage observed an increase of
endothelial cytoplasm density and a destruction of endothelial tight junctions in the ECs of muscle and skin biopsies in
CADASIL patients7. The abnormal changes of ECs were not
only observed in morphology, but also in function. EC dysfunction represents diminished production of nitric oxide, an
imbalanced endothelium-derived relaxing and contracting
factors, BBB leakage, and pro-thrombosis12,31,32. Peters and
colleagues performed a clinical trial in CADASIL patients
using L-arginine, which is a substrate for nitric oxide
synthase in ECs33. The findings of this clinical study showed
that there was impaired cerebral hemodynamics in

CADASIL patients and that L-arginine significantly
increased the vasoreactivity of these CADASIL patients.
These data reveal the EC dysfunction in CADASIL disease
and suggest that targeting EC dysfunction is a potential therapeutic strategy for CADASIL. Campolo and collaborators
also found that the functional alterations of ECs and smooth
muscle cells were involved in vasoreactivity impairments in
CADASIL patients34. Similar findings were also seen in the
transgenic mouse model carrying CADASIL-related
NOTCH3 mutation in the VSMCs (TgNotch3R90C) 26.
Recently, our lab has also observed endothelial damage in
the brains of TgNotch3R90C mice9. In addition, Ghosh and
colleagues reported that there were impairments of the BBB
in another transgenic mouse model of CADASIL
(TgNotch3R169C), further confirming the EC damage/dysfunction in CADASIL condition35.
In the present study, we have demonstrated that capillary
and small vessel thrombosis, endothelial damage and EC
replacement by bone marrow-derived cells in and next to
the thrombotic area, and capillary leakage all happen in the
brains of 22-month-old TgNotch3R90C mice. Particularly,
degenerated ECs are seen within the thrombotic region, indicating a vital role of EC damage in thrombotic formation.
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Bone marrow-derived ECs (CD31þ/GFPþ) appear in and
next to the thrombotic area, suggesting the damaged ECs
that have been replaced by bone marrow-derived progenitor
cells. In a mouse model of ischemic stroke, similar findings
were also reported by Hess and co-workers. They found that
the bone marrow-derived circulating endothelial progenitor
cells contributed to blood vessel repair after cerebral ischemia by forming new ECs and neovascularization36. The
newly generated cerebral vessels, however, can also lead
to BBB leakage37,38. Our data reveal a co-localization of
bone marrow-derived ECs, thrombotic formation, and BBB
leakage in the cerebral capillaries of TgNotch3R90C mice,
suggesting that the bone marrow endothelial progenitor cellreplaced/generated cerebral capillary ECs in TgNotch3R90C
mice may be dysfunctional. The dysfunctional bone marrowderived ECs may be also crucially involved in thrombotic
generation and BBB leakage in the brains of TgNotch3R90C
mice. It is worth noting that the most prominent thrombosis
occurs in the cerebral capillaries, suggesting the capillary
thrombosis is a key pathological feature in a CADASILlike condition. This discovery is in line with the clinical
findings showing that small and scattered infarcts (lacunar
infarcts or microinfarcts) are one of the unique pathological
signatures for CADASIL6,39, which is significantly different
from relatively larger artery thrombosis-caused large infarct
as seen in stroke patients. Cerebral vascular degenerationinduced disturbance of cerebral blood flow (CBF) and
endothelial damage in CADASIL condition are the key
players driving thrombotic formation. Although both the
control TgNotch3R90C mice and SCFþG-CSF-treated
TgNotch3R90C mice received an equal number of bone
marrow cells from UBC-GFP mice for bone marrow transplantation, only SCFþG-CSF-treated TgNotch3R90C mice
showed significant reductions in capillary thrombosis. These
findings suggest that the blood cells do not play a vital role
in triggering thrombotic formation. Taken together, all the
findings from both clinical trials and biomedical research
suggest that CADASIL is not limited to a VSMC degenerative disease, whereas the EC degeneration is also
involved in the development of CADASIL. The mechanism
of EC degeneration in CADASIL remains to be addressed
in future studies.

SCFþG-CSF Treatment Inhibits Capillary Thrombosis
and Leakage in the Brains of TgNotch3R90C Mice
EC damage and dysfunction is considered a chronic process
accompanied by a loss of antithrombotic factors, increases in
vasoconstrictor and pro-thrombotic products, and abnormal
vasoactivity31. EC damage/dysfunction leads to a myriad of
potential consequences, including inflammation, thrombosis, fibrosis, vessel occlusion, and vasoactivity impairments14. In addition, EC damage/dysfunction also causes
increased permeability of BBB and deposition of extracellular matrix 32 . The findings of the present study have
revealed that repeated treatment of SCFþG-CSF diminishes
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capillary thrombosis and capillary leakage in the brains of
22-month-old TgNotch3R90C mice. These data suggest that
SCFþG-CSF treatment may restrict cerebral capillary EC
damage/dysfunction under the CADASIL-like condition. In
line with our observation, Wei and colleagues recently
reported that G-CSF significantly attenuated IgG leakage
and reduced the BBB damage in spontaneous hypertensive
rats40. These findings provide further support for the potential contribution of hematopoietic growth factors in inhibiting EC damage in cerebrovascular diseases. On the other
hand, maintaining fibrinogen at physiological level may also
contribute to SCFþG-CSF-reduced cerebral EC damage and
thrombosis in 22- month-old TgNotch3R90C mice. Fibrinogen is a key protein component of blood clots. Increased
plasma fibrinogen has been found in the elderly41. Elevated
plasma fibrinogen leads to BBB leakage42,43 and cerebrovascular dysfunction44. Our recent study has revealed that
SCFþG-CSF treatment reduces the levels of plasma fibrinogen in aged mice with chronic stroke45. Further studies are
needed to clarify the pathological role of fibrinogen in
CADASIL-associated EC damage/dysfunction.
The cerebral capillary bed plays a key role in regulation
of CBF46. Recent studies have demonstrated that microvasculature and cerebral capillaries are the most vulnerable
vessels to be damaged and lost in the setting of ischemic
stroke47,48. It remains largely unknown whether cerebral
capillary is also affected by CADASIL and how the cerebral
capillary ECs are damaged in the CADASIL condition. It has
been shown that disturbed blood flow is a vital risk factor for
EC injury14. An increased cerebrovascular resistance and
decreased autoregulation of CBF have been found in
18-month-old TgNotch3R90C mice27. We postulate that cerebral capillary pathology and cerebral capillary EC damage
may be crucially involved in the disturbed CBF in the
22-month-old TgNotch3R90C mice. In support of this postulation, the findings of the present study have shown that
the incidence of thrombosis is increased significantly in the
cerebral capillaries, particularly in the bifurcation region of
the cerebral capillaries in the 22-month-old TgNotch3R90C
mice. Emerging evidence has shown that the number of
vascular bifurcations is dramatically increased in the cerebral capillaries as compared with other types of blood vessels49. It has been demonstrated that the unique geometry of
the vessel bifurcation leads to complex blood flow at the site
of bifurcation50. Together with the complex blood flow,
hemodynamic forces at the bifurcation area make the ECs
of bifurcation region more vulnerable to damage in the presence of risk factors for vascular diseases50–52. In the CADASIL condition, disturbed CBF with VSMC and pericyte
degeneration in cerebral small arteries and capillaries may
act as additional pathological elements to the capillary bifurcation area, resulting in increased EC damage and thrombotic formation in the region of capillary bifurcation.
Our previous study has revealed that VSMC degeneration
in cerebral small vessels of 22-month-old TgNotch3R90C
mice is reduced by SCFþG-CSF repeated treatment9. The
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present study has shown that SCFþG-CSF repeated treatment significantly reduces the formation of thrombosis in the
capillary branching area. These findings imply that a rebalanced CBF may be established in the brains of SCFþGCSF-treated 22-month-old TgNotch3R90C mice. Further
studies using live brain imaging would help in clarifying the
contribution of SCFþG-CSF treatment on restricting
CADASIL-induced impairment of CBF.
In summary, to the best of the authors’ knowledge, it is
the first time that cerebral capillary EC damage and cerebral
capillary thrombosis with a high rate in the capillary
branches have been demonstrated as additional key pathological features in transgenic mice with the CADASIL-like
condition. Repeated treatment of SCFþG-CSF inhibits
occurrence of these pathological events. These findings
would contribute to improving current understanding of
CADASIL pathogenesis and developing therapeutic strategies for CADASIL.
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